Here's more commentary and explanation on KV Pharma's new premie-prevention drug, Makena, and the pricing decisions aroudn it. KV is now also enforcing its rights as an orphan drug provider and it aggressively pursuing cease and desist letters with compounders who would copy (for real cheap) its drug.
In ints defense, KV points out that Makena is FDA approved, unlike products provided by compounders. It will also save money with its expected treatment course of $27,000-33,000 per patient versus an average cost of $51,000 to treat a premature newborn. Analysts say KV shyold be able to hit $1.1 B in annual sales of the new drug by 2015.
Stories from the WSJ Health blog and the Pharmalot blog.
Posted by Bruce Lehr Mar 10th 2011.
In the Pipeline (Mar 11th) weighs in with its analysis of this situation a byproduct of FDA putting its stamp of approval on the drug and the granting of orphan status
http://seekingalpha.com/article/257803-kv-pharmaceuticals-gets-away-with-pricing-on-makena
Posted by: bigredbruce | 03/11/2011 at 03:33 PM